ACCC Submits Comments to FDA on Draft Guidance to Increase Diversity in Clinical Trials

The ACCC Community Oncology Research Institute (ACORI) Task Force submitted comments to the Food and Drug Administration (FDA) in response to the agency's draft guidance on Diversity Plans to Improve Enrollment of Participants from Underrepresented Racial and Ethnic Populations in Clinical Trials.
Read the Letter